Zoryve (roflumilast) foam is an exciting, relatively new option for managing seborrheic dermatitis. It was FDA-approved in December 2023 for adults and children aged 9 and older.
Here's what makes it stand out:
- It's the first new seborrheic dermatitis treatment with a new mechanism of action in over 20 years
- It's Show Full Answer
Zoryve (roflumilast) foam is an exciting, relatively new option for managing seborrheic dermatitis. It was FDA-approved in December 2023 for adults and children aged 9 and older.
Here's what makes it stand out:
- It's the first new seborrheic dermatitis treatment with a new mechanism of action in over 20 years
- It's steroid-free and used just once daily
- It can be applied anywhere on the body, including areas with hair
- It works by calming inflammation through the immune system As for how people are doing on it, the clinical trial results are pretty encouraging:
- After 8 weeks, 80% of users achieved clear or almost clear skin
- 50% experienced complete clearance of symptoms
- Over 60% saw at least a significant reduction in itch severity
- Some people noticed improvement as early as 2 days in
- It was generally considered safe and well tolerated
If you're curious whether Zoryve might be a good fit, it's worth bringing up with your dermatologist. Reported side effects include cold-like symptoms, nausea, and headache, so that's something to keep in mind when having that conversation.
August 27
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
